OBJECTIVE: The purpose of this study was to determine whether second-trimester soluble fms-like tyrosine kinase-1 and placenta growth factor (PlGF) are altered in patients who have preeclampsia develop compared with controls. Furthermore, soluble fms-like tyrosine kinase-1 and placenta growth factor levels in patients with chronic hypertension are described. STUDY DESIGN: With the use of a research database, 21 patients who had severe preeclampsia develop, 34 controls, and 9 patients with chronic hypertension were enrolled. Placenta growth factor and soluble fms-like tyrosine kinase-1 serum levels were determined by enzyme-linked immunosorbent assay. Appropriate statistical tests were used and results were reported as median (quartile 1-quartile 3) in picograms per milliliter. RESULTS: Placenta growth factor was significantly lower in patients in the second trimester who later had severe preeclampsia develop but soluble fms-like tyrosine kinase-1 was unchanged compared with healthy pregnancies. In patients with chronic hypertension, placenta growth factor and soluble fms-like tyrosine kinase-1 levels were not different compared with controls. CONCLUSION: Second-trimester placenta growth factor levels are altered in patients who had severe preeclampsia develop.
OBJECTIVE: The purpose of this study was to determine whether second-trimester soluble fms-like tyrosine kinase-1 and placenta growth factor (PlGF) are altered in patients who have preeclampsia develop compared with controls. Furthermore, soluble fms-like tyrosine kinase-1 and placenta growth factor levels in patients with chronic hypertension are described. STUDY DESIGN: With the use of a research database, 21 patients who had severe preeclampsia develop, 34 controls, and 9 patients with chronic hypertension were enrolled. Placenta growth factor and soluble fms-like tyrosine kinase-1 serum levels were determined by enzyme-linked immunosorbent assay. Appropriate statistical tests were used and results were reported as median (quartile 1-quartile 3) in picograms per milliliter. RESULTS:Placenta growth factor was significantly lower in patients in the second trimester who later had severe preeclampsia develop but soluble fms-like tyrosine kinase-1 was unchanged compared with healthy pregnancies. In patients with chronic hypertension, placenta growth factor and soluble fms-like tyrosine kinase-1 levels were not different compared with controls. CONCLUSION: Second-trimester placenta growth factor levels are altered in patients who had severe preeclampsia develop.
Authors: Roberto Romero; Tinnakorn Chaiworapongsa; Offer Erez; Adi L Tarca; Maria Teresa Gervasi; Juan Pedro Kusanovic; Pooja Mittal; Giovanna Ogge; Edi Vaisbuch; Shali Mazaki-Tovi; Zhong Dong; Sun Kwon Kim; Lami Yeo; Sonia S Hassan Journal: J Matern Fetal Neonatal Med Date: 2010-05-12
Authors: Robert W Powers; James M Roberts; Daniel A Plymire; Dominick Pucci; Saul A Datwyler; Don M Laird; David C Sogin; Arun Jeyabalan; Carl A Hubel; Robin E Gandley Journal: Hypertension Date: 2012-05-29 Impact factor: 10.190
Authors: Donald Wothe; Emanuel Gaziano; Shiraz Sunderji; Roberto Romero; Juan Pedro Kusanovic; Linda Rogers; Cheryl Hodges-Savola; Sean Roberts; James Wassenberg Journal: Hypertens Pregnancy Date: 2010-05-19 Impact factor: 2.108
Authors: Amy E Whitten; Roberto Romero; Steven J Korzeniewski; Adi L Tarca; Alyse G Schwartz; Lami Yeo; Zhong Dong; Sonia S Hassan; Tinnakorn Chaiworapongsa Journal: Am J Obstet Gynecol Date: 2013-01-17 Impact factor: 8.661
Authors: Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Juan Pedro Kusanovic; Eleazar Soto; Jennifer Lam; Zhong Dong; Nandor G Than; Lami Yeo; Edgar Hernandez-Andrade; Agustín Conde-Agudelo; Sonia S Hassan Journal: Am J Obstet Gynecol Date: 2013-01-17 Impact factor: 8.661